MCM-2, Ki-67, and EGFR downregulated expression levels in advanced stage laryngeal squamous cell carcinoma

Autor: Komkrit Ruangritchankul, Thiratest Leesutipornchai, Patnarin Mahattanasakul, Sarocha Vivatvakin, Saknan Bongsebandhu-phubhakdi, Somboon Keelawat, Thanaporn Ratchataswan
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
Male
Cancer therapy
Severity of Illness Index
0302 clinical medicine
Medicine
Epidermal growth factor receptor
Head and neck cancer
Aged
80 and over
Multidisciplinary
biology
Middle Aged
Laryngeal squamous cell carcinoma
Prognosis
Immunohistochemistry
ErbB Receptors
030220 oncology & carcinogenesis
Ki-67
Carcinoma
Squamous Cell
Disease Progression
Female
Adult
medicine.medical_specialty
Science
Article
Cancer screening
03 medical and health sciences
Downregulation and upregulation
Internal medicine
Biomarkers
Tumor
Humans
Correlation test
Laryngeal Neoplasms
Aged
Neoplasm Staging
business.industry
Advanced stage
Significant difference
Diagnostic markers
Minichromosome Maintenance Complex Component 2
030104 developmental biology
Ki-67 Antigen
biology.protein
business
Follow-Up Studies
Zdroj: Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
ISSN: 2045-2322
Popis: We present the conceptual study investigated the capacity of minichromosome maintenance-2 (MCM-2), Ki-67, and epidermal growth factor receptor (EGFR) to assess the severity and progression of laryngeal squamous cell carcinoma (LSCC) disease and to study the correlations among these markers. A total of 30 patients with LSCC with immunohistochemistry (IHC) staining for MCM-2, Ki-67 and EGFR were examined. Mean expression levels of the three markers were evaluated for comparing between early and advanced stages of LSCC. The mean MCM-2, Ki-67, and EGFR expression levels were significantly decreased in advanced-stage compared with early-stage LSCC. Pearson correlation analysis showed a statistically significant correlation between the MCM-2 and Ki-67. Regarding subgroup analyses, MCM-2, Ki-67, and EGFR showed significant differences between early- and advanced-stage LSCC with non-recurrence, while for the recurrent subgroup LSCC, only MCM-2 revealed a significant difference between early- and advanced-stage LSCC. Altogether, these results support the role for downregulation of MCM-2, Ki-67 and EGFR in advanced-stage LSCC and correlation of MCM-2 and Ki-67 expressions that would be a promising strategy to predict prognosis of LSCC including severity and progression. We contextualize our findings and advocate the position of the biological markers, especially MCM-2, as an emerging evaluation tool for LSCC disease.
Databáze: OpenAIRE
Externí odkaz: